Aquestive Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Aquestive Therapeutics, Inc. (AQST) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 1.71 million shares for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-04.
Discontinued › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2021-05-04
- Aquestive Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2021-03-31 was 1.71M shares, a 9.10% increase year-over-year.
- Aquestive Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2020-03-31 was 1.57M shares.
- Aquestive Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2020 was 1.71M shares, a 9.10% increase from fiscal 2019.
- Aquestive Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2019 was 1.57M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2021-03-31 | 1.71M shares 10-Q · filed 2021-05-04 | |||
| 2020-12-31 | 1.71M shares 10-K · filed 2021-03-09 | |||
| 2020-09-30 | 4.66M shares 10-Q · filed 2020-11-04 | |||
| 2020-06-30 | 4.75M shares 10-Q · filed 2020-08-04 | |||
| 2020-03-31 | 1.57M shares 10-Q · filed 2021-05-04 | |||
| 2019-12-31 | 1.57M shares 10-K · filed 2021-03-09 | |||
| 2019-09-30 | 2.36M shares 10-Q · filed 2020-11-04 | |||
| 2019-06-30 | 2.13M shares 10-Q · filed 2020-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |